All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Does adding blinatumomab to frontline therapy improve survival outcomes for adults with B-ALL?
Featured
During the EHA 2022 Congress, the ALL Hub was pleased to speak to Anita Rijneveld, Erasmus MC, Rotterdam, NL. We asked, Does adding blinatumomab to frontline therapy improve survival outcomes for adults with B-ALL?
Does adding blinatumomab to frontline therapy improve survival outcomes for adults with B-ALL?
Rijneveld begins by stating the importance of MRD negativity in improving outcomes of ALL. Rijneveld then discusses the results of her phase II study, in which patients were given blinatumomab after consolidation therapy. Finally, Rijneveld talks about the D-ALBA trial, and using blinatumomab in combination with other drugs.
More about...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox